Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Wiesweg, Marcel [VerfasserIn]   i
 Küter, Claudia [VerfasserIn]   i
 Schnorbach, Johannes [VerfasserIn]   i
 Keyl, Julius [VerfasserIn]   i
 Metzenmacher, Martin [VerfasserIn]   i
 Cvetkovic, Jelena [VerfasserIn]   i
 Saalfeld, Felix [VerfasserIn]   i
 Glanemann, Franziska [VerfasserIn]   i
 Eberhardt, Wilfried [VerfasserIn]   i
 Oezkan, Filiz [VerfasserIn]   i
 Theegarten, Dirk [VerfasserIn]   i
 Stenzinger, Albrecht [VerfasserIn]   i
 Darwiche, Kaid [VerfasserIn]   i
 Koschel, Dirk [VerfasserIn]   i
 Herth, Felix [VerfasserIn]   i
 Bölükbas, Servet [VerfasserIn]   i
 Winter, Hauke [VerfasserIn]   i
 Weykamp, Fabian [VerfasserIn]   i
 Wermke, Martin [VerfasserIn]   i
 Stuschke, Martin [VerfasserIn]   i
 Plönes, Till [VerfasserIn]   i
 Thomas, Michael [VerfasserIn]   i
 Schuler, Martin [VerfasserIn]   i
 Christopoulos, Petros [VerfasserIn]   i
Titel:Oligometastatic non-small cell lung cancer
Titelzusatz:impact of local and contemporary systemic treatment approaches on clinical outcome
Verf.angabe:Marcel Wiesweg, Claudia Küter, Johannes Schnorbach, Julius Keyl, Martin Metzenmacher, Jelena Cvetkovic, Felix Carl Saalfeld, Franziska Glanemann, Wilfried Eberhardt, Filiz Oezkan, Dirk Theegarten, Albrecht Stenzinger, Kaid Darwiche, Dirk Koschel, Felix Herth, Servet Bölükbas, Hauke Winter, Fabian Weykamp, Martin Wermke, Martin Stuschke, Till Plönes, Michael Thomas, Martin Schuler, Petros Christopoulos
E-Jahr:2024
Jahr:[25 September 2024]
Umfang:12 S.
Fussnoten:Gesehen am 14.05.2025
Titel Quelle:Enthalten in: International journal of cancer
Ort Quelle:Bognor Regis : Wiley-Liss, 1966
Jahr Quelle:2025
Band/Heft Quelle:156(2025), 4, Seite 776-787
ISSN Quelle:1097-0215
Abstract:Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches is lacking, in particular with respect to the integration of immunotherapy. This real-world study identified 218 patients with OMD NSCLC (2004-2023, prespecified criteria: ≤5 metastases in ≤2 organ systems) from three major German comprehensive cancer centers. Most patients had one (72.5%) or two (17.4%) metastatic lesions in a single (89.9%) organ system. Overall survival (OS) was significantly longer with a single metastatic lesion (HR 0.54, p = .003), and female gender (HR 0.4, p < .001). Median OS of the full cohort was 27.8 months, with 29% survival at 5 years. Patients who had completed LAT to all NSCLC sites, typically excluding patients with early progression, had a median OS of 34.4 months (37.7% 5-year OS rate) with a median recurrence-free survival (RFS) of 10.9 months (13.3% at 5 years). In those patients, systemic treatment as part of first-line therapy was associated with doubling of RFS (12.3 vs. 6.4 months, p < .001). Despite limited follow-up of patients receiving chemo-immunotherapy (EU approval 2018/2019), RFS was greatly improved by adding checkpoint inhibitors to chemotherapy (HR 0.44, p = .008, 2-year RFS 51.4% vs. 15.1%). In conclusion, patients with OMD NSCLC benefitted from multimodality approaches integrating systemic therapy and local ablation of all cancer sites. A substantial proportion of patients achieved extended OS, suggesting a potential for cure that can be further augmented with the addition of immunotherapy.
DOI:doi:10.1002/ijc.35199
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1002/ijc.35199
 kostenfrei: Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.35199
 DOI: https://doi.org/10.1002/ijc.35199
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:immunotherapy
 locally ablative treatment
 multimodal concepts
 observational study
 oligometastatic NSCLC
K10plus-PPN:192566614X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69344856   QR-Code
zum Seitenanfang